Stoke Therapeutics, Inc. STOK AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s AFS securities?
- Stoke Therapeutics, Inc. (STOK) reported AFS securities of $67.48M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s AFS securities changed year-over-year?
- Stoke Therapeutics, Inc.'s AFS securities increased by 193.5% year-over-year, from $22.99M to $67.48M.
- What does AFS securities mean?
- Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.